 IRVINE, Calif., April 05, 2021 GLOBE NEWSWIRE -- Inari Medical, Inc. NASDAQ: NARI Inari, a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced the enrollment of the first high-risk pulmonary embolism PE patient in the FlowTriever for Acute Massive Pulmonary Embolism study FLAME. One in 20 PE diagnoses is categorized as high-risk and these are associated with a mortality rate of up to 40 at 90 days. 